MULTIPARAMETRIC MpMRI: 17/02/2025 HYGEIA – DEPARTMENT OF CT & MRI SCANNING AND BONE DENSITY MEASUREMENT MC...
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Question asked:
MULTIPARAMETRIC MpMRI: [date removed] HYGEIA – DEPARTMENT OF CT & MRI SCANNING AND BONE DENSITY MEASUREMENT MC responsibility 40h REGISTRATION No.: ……… DATE OF BIRTH: ………… CASE CODE: ……… EXAM DATE: [date removed] FULL NAME: …………… EXAM TIME: 15:01 MULTIPARAMETRIC MRI OF THE PROSTATE GLAND – TECHNIQUE: The examination was performed on a 3-Tesla system using a dedicated surface coil. The study included axial, coronal, and sagittal sections with various T1- and T2-weighted sequences, with and without fat suppression, axial diffusion-weighted imaging, as well as dynamic contrast-enhanced imaging. FINDINGS: The prostate gland measures 4 × 2.7 cm in axial dimensions and 3.2 cm in craniocaudal diameter. Mild adenomatous hyperplasia is observed in the transitional zone of the gland. At the apex of the left lobe of the gland, in its inferior portion, along the 3–5 o’clock axis, a lesion measuring 1 cm in diameter is identified. It demonstrates restricted diffusion and shows intense early contrast enhancement. It is considered suspicious for clinically significant neoplasia. The lesion causes mild indentation of the prostatic capsule. The seminal vesicles appear normal. No gross wall abnormality is observed in the urinary bladder. No enlarged periprostatic lymph nodes are visualized. CONCLUSION: PI-RADS 4 lesion at the apex of the left lobe of the prostate gland.
Your Prostate MRI Results: Educational Interpretation
Thank you for sharing your MRI report. This is important information that requires careful discussion with your urologist. Let me help you understand what these findings mean.
Your MRI Findings Explained
Prostate Size & General Health
- Prostate dimensions: 4 × 2.7 × 3.2 cm — This is a normal size for a 71-year-old man
- Mild adenomatous hyperplasia: This is benign enlargement of the transitional zone (inner part of the prostate), very common with age and not cancer
- Seminal vesicles: Normal
- Bladder: Normal
- Lymph nodes: No enlargement
✅ These findings are reassuring.
The Key Finding: PI-RADS 4 Lesion
This is the clinically significant part of your report. Let me break it down:
What was found:
- Location: Apex (tip) of the left lobe, lower portion (3-5 o'clock position)
- Size: 1 cm (about the size of a small pea)
- Appearance:
- Restricted diffusion (water movement is limited—suggests abnormal tissue)
- Intense early contrast enhancement (takes up dye quickly—suggests active tissue)
- Mild capsule indentation (slightly pushing on the prostate's outer lining)
What PI-RADS 4 means:
PI-RADS (Prostate Imaging-Reporting and Data System) is a standardized scoring system radiologists use to assess prostate lesions:
| PI-RADS Score | Clinical Meaning | |---|---| | 1-2 | Very unlikely to be clinically significant cancer | | 3 | Intermediate concern | | 4 | Likely to be clinically significant cancer | | 5 | Very likely to be clinically significant cancer |
In plain language: A PI-RADS 4 lesion is suspicious for clinically significant prostate cancer and typically warrants further investigation.
How This Connects to Your Rising PSA
This is important context:
- Your PSA rose from 4.1 to 5.14 ng/mL over 3 months (which we discussed)
- Your May 2024 exam was normal (digital rectal exam, ultrasound)
- Now your MRI shows a suspicious lesion at the same location where PSA-producing tissue is concentrated
This pattern suggests: The rising PSA and the MRI finding are likely related—the lesion may be responsible for your PSA increase.
Clinical Decision-Making: What Happens Next
According to NCCN Guidelines for Prostate Cancer Diagnosis and Management, when a PI-RADS 4 lesion is found:
Doctors typically recommend:
- Targeted prostate biopsy — Using MRI guidance to biopsy the specific lesion
- Risk stratification — Determining your overall prostate cancer risk based on all findings
- Shared decision-making — Discussing options with you based on your preferences and life expectancy
Why biopsy? A PI-RADS 4 lesion is suspicious but not diagnostic. Only a tissue sample can confirm whether this is:
- Clinically significant prostate cancer
- Benign tissue that mimics cancer on imaging
- Low-risk cancer that might be monitored rather than treated
What You Should Know About Biopsy
MRI-guided biopsy (also called targeted biopsy) is the standard approach for PI-RADS 4 lesions because:
- ✅ It targets the specific suspicious area
- ✅ It's more accurate than random sampling
- ✅ It provides tissue diagnosis
- ✅ It helps determine cancer grade and aggressiveness (if cancer is present)
The procedure:
- Usually done as an outpatient procedure
- Takes 15-30 minutes
- Local anesthesia is used
- Multiple small tissue samples are taken
- Results typically available in 5-7 days
Critical Questions for Your Urologist
Given this MRI finding, these questions are essential:
-
"Based on this PI-RADS 4 lesion and my rising PSA, do you recommend an MRI-guided biopsy? Why or why not?"
-
"If we do a biopsy, what will it tell us, and how will the results guide treatment decisions?"
-
"What are the risks and benefits of biopsy versus active surveillance in my case?"
-
"If cancer is found, what factors will determine whether I need treatment versus monitoring?"
-
"Given my age (71) and overall health, what is your recommendation for next steps?"
-
"Can you explain my individual risk based on PSA level, MRI findings, and other factors?"
-
"What is the timeline for the next step—should this be done urgently or can we take time to discuss options?"
Important Context: Your Individual Situation
Factors your doctor will consider:
✅ Reassuring:
- Normal digital rectal exam (May 2024)
- Normal ultrasound (May 2024)
- Lesion is small (1 cm)
- No lymph node involvement
- No distant spread
⚠️ Requiring evaluation:
- PI-RADS 4 lesion (suspicious)
- Rising PSA trend
- Age 71 (life expectancy matters in prostate cancer decisions)
What the Medical Guidelines Say
According to NCCN Clinical Practice Guidelines for Prostate Cancer:
- PI-RADS 4 lesions warrant further evaluation, typically with targeted biopsy
- Risk stratification (combining PSA, imaging, and clinical findings) guides treatment decisions
- Shared decision-making is essential, especially in older men where life expectancy and treatment preferences matter significantly
- Active surveillance is an option for some men with low-risk or very early-stage disease
According to the American Cancer Society:
- Men age 70+ should have individualized discussions about screening and diagnosis
- Treatment decisions should consider life expectancy, overall health, and patient preferences
Next Steps: Your Action Plan
Immediate:
- ✅ Schedule an appointment with your urologist to discuss the MRI results
- ✅ Bring this report and your PSA trend data
- ✅ Prepare your questions (use the list above)
At your appointment, clarify:
- Does your urologist recommend biopsy?
- What is the timeline?
- What are your options if cancer is found?
- What does active surveillance mean in your case?
Before biopsy (if recommended):
- Ask about preparation instructions
- Discuss antibiotic prophylaxis (infection prevention)
- Arrange transportation if sedation is used
- Plan for recovery time
Bottom Line
Your MRI shows a suspicious lesion that requires further evaluation. This is not a diagnosis of cancer—it's a finding that warrants a tissue diagnosis through biopsy. Your urologist will help you decide whether biopsy is appropriate and discuss what happens next based on the results.
The combination of your rising PSA and this MRI finding suggests your doctor will likely recommend biopsy to determine what this lesion actually is. This is a standard, appropriate next step.
Your role: Ask questions, understand your options, and participate in shared decision-making with your care team.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with clinical trials for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2